Relapsed / refractory (R/R)
Relapsed means the cancer came back after responding; refractory means it never responded or grew during treatment. 'R/R' is the label on most trials of new blood cancer drugs.
The distinction matters for prognosis and drug choice: refractory disease is biologically more resistant, and the interval to relapse (early relapse within 12 months of chemoimmunotherapy in lymphoma, platinum-resistant relapse within 6 months in ovarian cancer) is itself a stratification factor. Regulators define trial populations by prior lines and drug classes, so terms such as 'triple-class refractory' (myeloma resistant to a proteasome inhibitor, an immunomodulator and a CD38 antibody) or 'BCG-unresponsive' bladder cancer describe specific unmet needs that new drugs are approved for. Most accelerated approvals are in R/R settings before drugs move to earlier lines.
Pages like this
not linked directly; found by shared links- TermProject FrontRunner
Shares Lines of therapy, Accelerated approval.
- TermRefractory
Shares Lines of therapy, Accelerated approval, Drug resistance (primary and acquired).
- IdeaMake post-progression sampling a condition of accelerated approval
Shares Accelerated approval, Drug resistance (primary and acquired).
- TermCross-resistance
Shares Lines of therapy, Drug resistance (primary and acquired).
- TermProgression
Shares Lines of therapy, Drug resistance (primary and acquired).
- Key paperCodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug
Shares Accelerated approval, Drug resistance (primary and acquired).
- Key paperBREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer
Shares Lines of therapy, Accelerated approval.
- Key paperFLAURA: osimertinib as first treatment for EGFR-mutated lung cancer
Shares Lines of therapy, Drug resistance (primary and acquired).